Related Experiment Videos
[Chronic myeloproliferative diseases]
1Semmelweis Orvostudományi Egyetem, Budapest.
Insights
Chronic myeloproliferative diseases are bone marrow stem cell disorders characterized by excess blood cell production. Advances in treating chronic myelogenous leukemia include bone marrow transplantation and interferon therapy.
Area of Science:
- Hematology
- Oncology
- Stem Cell Biology
Background:
- Chronic myeloproliferative diseases (CMPDs) are a group of bone marrow stem cell disorders.
- Characterized by the overproduction of one or more blood cell types.
- Key CMPDs include chronic myelogenous leukemia, polycythemia rubra vera, osteomyelosclerosis/agnogenic myeloid metaplasia, and essential thrombocythemia.
Purpose of the Study:
- To provide an overview of chronic myeloproliferative diseases.
- To discuss their characteristics, clinical findings, and transformations.
- To highlight therapeutic advancements in CMPDs.
Main Methods:
- Review of the pathophysiology of CMPDs.
- Description of characteristic clinical findings like splenomegaly and bone marrow transformation.
- Summary of current and emerging therapeutic strategies.
Main Results:
- Abnormal control of cell division leads to excess blood cell accumulation.
- Bone marrow fibrosis and extramedullary hematopoiesis are common.
- Significant therapeutic progress has been made, particularly for chronic myelogenous leukemia.
Conclusions:
- CMPDs are heterogeneous stem cell disorders with shared features.
- Therapeutic options like bone marrow transplantation and interferon are established for certain CMPDs.
- New agents such as anagrelide show promise for myeloproliferative thrombocytosis.
Abstract:
The chronic myeloproliferative syndromes are bone marrow stem cell disorders. An increase of cell counts of one or rather all three blood cell types is characteristic for these disorders. The most important diseases in this group are: chronic myelogenous/granulocytic leukemia, polycythemia rubra vera, osteomyelosclerosis or agnogenic myeloid metaplasia and essential thrombocythemia. The cells are normally differentiating in these diseases, while the control of cell dividing is abnormal and therefore the cells are produced and accumulated in excess. Splenomegaly is a common and characteristic clinical finding. The fibrotic or sclerotic transformation of the bone marrow can take place in all forms of the syndrome. Extramedullary haematopoiesis can occur in all of the above diseases, but it is most common in myelofibrosis/agnogenic myeloid metaplasia. In the last phase of the disease a terminal blastic crisis may terminate the course of chronic myeloproliferative diseases. The myeloproliferative disorders can be transformed in each other--the most common transformation is that of the polycythemia rubra vera into myelofibrosis. The greatest progress in the therapy of chronic myeloproliferative diseases is achieved in chronic myelogenous leukemia: bone marrow transplantation and interferon treatment (the latter also in essential thrombocythemia and polycythemia rubra vera) are routine modalities worldwide. A new drug, anagrelide is effective in the treatment of myeloproliferative thrombocytosis and thrombocythemia.